BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 14599864)

  • 1. Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission.
    Tournigand C; Louvet C; Molitor JL; Fritel X; Dehni N; Sezeur A; Pigné A; Cady J; Milliez J; de Gramont A
    Gynecol Oncol; 2003 Nov; 91(2):341-5. PubMed ID: 14599864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
    Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of ifosfamide and cisplatinum in advanced ovarian cancer.
    Aziz Z; Zahid M; Ud Din Ahmed Z; Arshad T
    Aust N Z J Med; 1998 Jun; 28(3):403-9. PubMed ID: 9673759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer.
    Kirmani S; Braly PS; McClay EF; Saltzstein SL; Plaxe SC; Kim S; Cates C; Howell SB
    Gynecol Oncol; 1994 Sep; 54(3):338-44. PubMed ID: 8088611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
    Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
    Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.
    Beller U; Speyer J; Colombo N; Sorich J; Wernz J; Hochster H; Zeleniuch-Jacquotte A; Porges R; Beckman EM
    J Clin Oncol; 1991 May; 9(5):809-17. PubMed ID: 2016624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission.
    Dufour P; Bergerat JP; Barats JC; Giron C; Duclos B; Dellenbach P; Ritter J; Renaud R; Audhuy B; Oberling F
    Cancer; 1994 Apr; 73(7):1865-9. PubMed ID: 8137212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer.
    Topuz E; Eralp Y; Saglam S; Saip P; Aydiner A; Berkman S; Yavuz E
    Gynecol Oncol; 2004 Jan; 92(1):147-51. PubMed ID: 14751150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
    Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C
    Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.
    Konner JA; Grabon DM; Gerst SR; Iasonos A; Thaler H; Pezzulli SD; Sabbatini PJ; Bell-McGuinn KM; Tew WP; Hensley ML; Spriggs DR; Aghajanian CA
    J Clin Oncol; 2011 Dec; 29(35):4662-8. PubMed ID: 22067389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment.
    Barakat RR; Almadrones L; Venkatraman ES; Aghajanian C; Brown C; Shapiro F; Curtin JP; Spriggs D
    Gynecol Oncol; 1998 Apr; 69(1):17-22. PubMed ID: 9570993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
    Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial.
    Shi T; Jiang R; Yu J; Yang H; Tu D; Dai Z; Shen Y; Zhang Y; Cheng X; Jia H; Tu R; Wang H; Tang J; Luan Y; Cai S; Zang R;
    Br J Cancer; 2018 Jul; 119(1):12-18. PubMed ID: 29899395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer.
    Hunter RE; Griffin TW; Stevens S; Roman LD; Bokhari F; Reale FR; Tak WK; Fitzgerald TJ; Dillon MB; Rose PG
    Cancer; 1991 Nov; 68(9):1890-4. PubMed ID: 1655227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
    J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
    J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
    Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.